• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 174-188 of 313 results

1008 Exhibit: US Patent Publ No 20100029781

Document IPR2019-00207, No. 1008-7 Exhibit - US Patent Publ No 20100029781 (P.T.A.B. Nov. 6, 2018)

cite Cite Document
Analyze

1018 Exhibit: Gilmore Declaration

Document IPR2019-00207, No. 1018-31 Exhibit - Gilmore Declaration (P.T.A.B. Nov. 6, 2018)

cite Cite Document
Analyze

2034 Exhibit: Exhibit 2034 Tanghetti et al 2011

Document IPR2019-00207, No. 2034-65 Exhibit - Exhibit 2034 Tanghetti et al 2011 (P.T.A.B. Aug. 9, 2019)
Continuous accumulation of sebum and deposition of keratinous material lead to development of le sions (open and closed comedones) traditionally classified as noninflammatory or, with proliferation of Propionibacte rium acnes and induction of immunomodulatory events, in flammatory lesions.
22 Moreover, unlike lesion counts, subjective global assessments consider other signs and symptoms, such as erythema and oiliness among others, in the determination of acne severity, and thus more accurately reflect the pleomorphic nature of this disease.
How ever, alternative hypotheses to explain our findings are also possible, including that dapsone may have as-yet unidentified direct effects on keratinization, corneocyte adhesion, or even sebaceous gland output that might result in comedolysis un related to anti-inflammatory mechanisms.
Abe M, Shimizu A Yokoyama Y, et al. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha produc tion from activated mononuclear cells on cutaneous lupus erythe matosus.
Langner A Sheehan-Dare R, Layton A. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris.
cite Cite Document
Analyze

2025 Exhibit: Exhibit 2025 Kraft et al 2011

Document IPR2019-00207, No. 2025-56 Exhibit - Exhibit 2025 Kraft et al 2011 (P.T.A.B. Aug. 9, 2019)

cite Cite Document
Analyze

2010 Exhibit: Exhibit 2010 Collier et al 2008

Document IPR2019-00207, No. 2010-41 Exhibit - Exhibit 2010 Collier et al 2008 (P.T.A.B. Aug. 9, 2019)

cite Cite Document
Analyze

2021 Exhibit: Exhibit 2021 Kircik et al 2010a

Document IPR2019-00207, No. 2021-52 Exhibit - Exhibit 2021 Kircik et al 2010a (P.T.A.B. Aug. 9, 2019)

cite Cite Document
Analyze

2050 Exhibit: Exhibit 2050 FDA Inactive Ingredient Database September 2012

Document IPR2019-00207, No. 2050-81 Exhibit - Exhibit 2050 FDA Inactive Ingredient Database September 2012 (P.T.A.B. Aug. 9, 2019)

cite Cite Document
Analyze

2055 Exhibit: Exhibit 2055 Kircik Decl ISO Patent Owners Response

Document IPR2019-00207, No. 2055-86 Exhibit - Exhibit 2055 Kircik Decl ISO Patent Owners Response (P.T.A.B. Aug. 9, 2019)

cite Cite Document
Analyze

2037 Exhibit: Exhibit 2037 Thielitz et al 2008

Document IPR2019-00207, No. 2037-68 Exhibit - Exhibit 2037 Thielitz et al 2008 (P.T.A.B. Aug. 9, 2019)

cite Cite Document
Analyze

3002 Exhibit: Ex 3002

Document IPR2019-00207, No. 3002-150 Exhibit - Ex 3002 (P.T.A.B. Aug. 20, 2020)

cite Cite Document
Analyze

1074 Exhibit: Aczone DFD

Document IPR2019-00207, No. 1074-132 Exhibit - Aczone DFD (P.T.A.B. Nov. 1, 2019)

cite Cite Document
Analyze

1064 Exhibit: Kircik DFD 2014

Document IPR2019-00207, No. 1064-122 Exhibit - Kircik DFD 2014 (P.T.A.B. Nov. 1, 2019)

cite Cite Document
Analyze

1052 Exhibit: DMF approval database

Document IPR2019-00207, No. 1052-113 Exhibit - DMF approval database (P.T.A.B. Nov. 1, 2019)

cite Cite Document
Analyze

1041 Exhibit: Allergan Announces Agreement to Acquire Aczone¿¿ Gel

Document IPR2019-00207, No. 1041-105 Exhibit - Allergan Announces Agreement to Acquire Aczone¿¿ Gel (P.T.A.B. Nov. 1, 2019)

cite Cite Document
Analyze

1035 Exhibit: Poster Abstracts for the Journal of the American Academy of Dermat...

Document IPR2019-00207, No. 1035-98 Exhibit - Poster Abstracts for the Journal of the American Academy of Dermatology 2017 Annual Meeting served October 4, 2019 Part 3 (P.T.A.B. Oct. 18, 2019)

cite Cite Document
Analyze
<< 1 2 3 4 5 ... 12 13 14 15 16 ... >>